Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 1.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,210,428 shares of the company's stock after purchasing an additional 35,192 shares during the period. Van ECK Associates Corp owned approximately 0.07% of Takeda Pharmaceutical worth $29,266,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in TAK. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at approximately $40,000. BNP Paribas Financial Markets raised its holdings in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares in the last quarter. Smithfield Trust Co raised its holdings in Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after acquiring an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new position in Takeda Pharmaceutical in the 3rd quarter valued at approximately $52,000. Institutional investors and hedge funds own 9.17% of the company's stock.
Takeda Pharmaceutical Stock Performance
Takeda Pharmaceutical stock traded up $0.38 during trading hours on Tuesday, hitting $13.92. The stock had a trading volume of 1,008,477 shares, compared to its average volume of 1,921,955. The company has a 50-day moving average of $13.26 and a two-hundred day moving average of $13.87. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The company has a market cap of $44.28 billion, a PE ratio of 34.79, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.
Takeda Pharmaceutical Profile
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
